The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Non-gastric Marginal Zone B-cell Lymphoma in Korea: Clinical Features, Treatment, and Prognostic Factors

  • Oh, Sung-Yong (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Suh, Cheol-Won (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine)
  • Published : 2010.09.01
⟨ Previous Next ⟩

Abstract

Marginal zone B-cell lymphoma (MZL) is the second most common subtype of non-Hodgkin's lymphoma in Korea (17.3%). Mucosa-associated lymphoid tissue (MALT) can develop in almost any organ as a result of exposure to a persistent stimulus, such as chronic infection or certain autoimmune processes. Under conditions of prolonged lymphoid proliferation, a malignant clone may emerge, which is followed by the development of a MALT lymphoma. Whereas MALT lymphoma of the stomach is the most common and the most extensively studied, we focus on non-gastric MZL studies conducted in Korea that highlight the most recent advances with respect to MZL definition, etiology, clinical characteristics, natural history, treatment approaches, outcomes, and prognostic factors. Moreover, we discuss current organ-specific considerations and controversies, and identify areas for future research.

Keywords

Acknowledgement

Supported by : Dong-A University

References

  1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Pathology and Genetics of Tumours of Haematolopoietic and Lymphoid Tisses. Lyon: IARC Press, 2008.
  2. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003;101:2489-2495. https://doi.org/10.1182/blood-2002-04-1279
  3. Zinzani PL, Magagnoli M, Galieni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 1999;17:1254.
  4. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000;95:802-806.
  5. Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 1998;83:806-812. https://doi.org/10.1002/(SICI)1097-0142(19980815)83:4<806::AID-CNCR26>3.0.CO;2-V
  6. Won YJ, Sung J, Jung KW, et al. Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 2009;41:122-131. https://doi.org/10.4143/crt.2009.41.3.122
  7. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89: 3909-3918.
  8. Wotherspoon AC. Gastric MALT lymphoma and Helicobacter pylori. Yale J Biol Med 1996;69:61-68.
  9. Roggero E, Zucca E, Mainetti C, et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 2000;31:263-268. https://doi.org/10.1016/S0046-8177(00)80233-6
  10. Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004;96:586-594. https://doi.org/10.1093/jnci/djh102
  11. Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004;350:239-248. https://doi.org/10.1056/NEJMoa031887
  12. Hyjek E, Isaacson PG. Primary B cell lymphoma of the thyroid and its relationship to Hashimoto's thyroiditis. Hum Pathol 1988;19:1315-1326. https://doi.org/10.1016/S0046-8177(88)80287-9
  13. Isaacson PG. Extranodal lymphomas: the MALT concept. Verh Dtsch Ges Pathol 1992;76:14-23.
  14. Yoo C, Ryu MH, Huh J, et al. Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea. Am J Hematol 2007;82:821-823. https://doi.org/10.1002/ajh.20962
  15. Kim TM, Kim KH, Lee MJ, et al. First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of clinical predictors. Cancer Sci 2010;101:1199-1203. https://doi.org/10.1111/j.1349-7006.2010.01502.x
  16. Kim JH, Kim WS, Ko YH, et al. Clinical investigation of gastric MALT lymphoma. Korean J Med 2001;61:417-423.
  17. Oh SY, Kim WS, Kim JH, et al. Extra-gastric MALT lymphoma:Analysis of 50 cases. Korean J Med 2000;59:261-267.
  18. Oh SY, Ryoo BY, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol 2007;82:446-452. https://doi.org/10.1002/ajh.20874
  19. Oh SY, Ryoo BY, Kim WS, et al. Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol 2006;85:781-786. https://doi.org/10.1007/s00277-006-0160-y
  20. Oh SY, Kim WS, Kim SJ, et al. Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases. Am J Hematol 2009;84:826-829. https://doi.org/10.1002/ajh.21557
  21. Kang HJ, Ryoo BY, Suh C, et al. Rituximab plus CVP (cyclophosphamide, vincristine, and prednisolone) combination chemotherapy on advanced stage marginal zone B-cell lymphoma. Haematologica 2010;95(s2):623.
  22. Suh C, Huh J, Roh JL. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the extracranial head and neck region: a high rate of dissemination and disease recurrence. Oral Oncol 2008;44:949-955. https://doi.org/10.1016/j.oraloncology.2007.11.011
  23. Isaacson PG. Update on MALT lymphomas. Best Pract Res Clin Haematol 2005;18:57-68. https://doi.org/10.1016/j.beha.2004.08.003
  24. Zucca E, Bertoni F, Stathis A, Cavalli F. Marginal zone lymphomas. Hematol Oncol Clin North Am 2008;22:883-901. https://doi.org/10.1016/j.hoc.2008.07.011
  25. Ferreri AJ, Zucca E. Marginal-zone lymphoma. Crit Rev Oncol Hematol 2007;63:245-256. https://doi.org/10.1016/j.critrevonc.2007.04.009
  26. Oh SY, Kim WS, Lee DH, et al. Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Invest New Drugs 2010;28:171-177. https://doi.org/10.1007/s10637-009-9260-6
  27. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994. https://doi.org/10.1056/NEJM199309303291402
  28. Lopez-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994;12:1343-1348.
  29. Foussard C, Desablens B, Sensebe L, et al. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France. Ann Oncol 1997;8 Suppl 1:49-52. https://doi.org/10.1093/annonc/8.suppl_1.S49
  30. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265. https://doi.org/10.1182/blood-2003-12-4434
  31. Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone Bcell lymphoma: a clinical comparison of nodal and mucosaassociated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1999;17:2486-2492.
  32. Oh SY, Kwon HC, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. Cancer Lett 2007;258:90-97. https://doi.org/10.1016/j.canlet.2007.08.012
  33. Oh DE, Kim YD. Lymphoproliferative diseases of the ocular adnexa in Korea. Arch Ophthalmol 2007;125:1668-1673. https://doi.org/10.1001/archopht.125.12.1668
  34. Cho EY, Han JJ, Ree HJ, et al. Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone b-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients. Am J Hematol 2003;73:87-96. https://doi.org/10.1002/ajh.10332
  35. Yoon JS, Ma KT, Kim SJ, Kook K, Lee SY. Prognosis for patients in a Korean population with ocular adnexal lymphoproliferative lesions. Ophthal Plast Reconstr Surg 2007;23:94-99. https://doi.org/10.1097/IOP.0b013e318030b058
  36. Lee JL, Kim MK, Lee KH, et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol 2005;84:13-18. https://doi.org/10.1007/s00277-004-0914-3
  37. Suh CO, Shim SJ, Lee SW, Yang WI, Lee SY, Hahn JS. Orbital marginal zone B-cell lymphoma of MALT: radiotherapy results and clinical behavior. Int J Radiat Oncol Biol Phys 2006;65:228-233. https://doi.org/10.1016/j.ijrobp.2005.11.035
  38. Nam H, Ahn YC, Kim YD, Ko Y, Kim WS. Prognostic significance of anatomic subsites: results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma. Radiother Oncol 2009;90:236-241. https://doi.org/10.1016/j.radonc.2008.09.011
  39. Son SH, Choi BO, Kim GW, et al. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma). Int J Radiat Oncol Biol Phys 2010;77:86-91. https://doi.org/10.1016/j.ijrobp.2009.04.018
  40. Song EK, Kim SY, Kim TM, et al. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone Bcell lymphoma. Ann Oncol 2008;19:242-246. https://doi.org/10.1093/annonc/mdm457
  41. Ferraro P, Trastek VF, Adlakha H, Deschamps C, Allen MS, Pairolero PC. Primary non-Hodgkin's lymphoma of the lung. Ann Thorac Surg 2000;69:993-997. https://doi.org/10.1016/S0003-4975(99)01535-0
  42. Ahmed S, Siddiqui AK, Rai KR. Low-grade B-cell bronchial associated lymphoid tissue (BALT) lymphoma. Cancer Invest 2002;20:1059-1068. https://doi.org/10.1081/CNV-120005924
  43. Ahmed S, Kussick SJ, Siddiqui AK, et al. Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease. Eur J Cancer 2004;40:1320-1326. https://doi.org/10.1016/j.ejca.2004.02.006
  44. Zinzani PL, Poletti V, Zompatori M, et al. Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. Clin Lymphoma Myeloma 2007;7:566-572. https://doi.org/10.3816/CLM.2007.n.042
  45. Oh SY, Kim WS, Kim JS, et al. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol 2010;89:563-568. https://doi.org/10.1007/s00277-009-0875-7
  46. Bae YA, Lee KS, Han J, et al. Marginal zone B-cell lymphoma of bronchus-associated lymphoid tissue: imaging findings in 21 patients. Chest 2008;133:433-440. https://doi.org/10.1378/chest.07-1956
  47. Xu HY, Jin T, Li RY, Ni YM, Zhou JY, Wen XH. Diagnosis and treatment of pulmonary mucosa-associated lymphoid tissue lymphoma. Chin Med J (Engl) 2007;120:648-651.
  48. Kim JH, Lee SH, Park J, et al. Primary pulmonary non-Hodgkin's lymphoma. Jpn J Clin Oncol 2004;34:510-514. https://doi.org/10.1093/jjco/hyh095
  49. Stefanovic A, Morgensztern D, Fong T, Lossos IS. Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database. Leuk Lymphoma 2008;49:1311-1320. https://doi.org/10.1080/10428190802064933
  50. Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001; 19:3861-3873.
  51. Kohno S, Ohshima K, Yoneda S, Kodama T, Shirakusa T, Kikuchi M. Clinicopathological analysis of 143 primary malignant lymphomas in the small and large intestines based on the new WHO classification. Histopathology 2003;43:135-143. https://doi.org/10.1046/j.1365-2559.2003.01659.x
  52. Oh SY, Kwon HC, Kim WS, et al. Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. Eur J Haematol 2007;79:287-291. https://doi.org/10.1111/j.1600-0609.2007.00925.x
  53. Conconi A, Bertoni F, Pedrinis E, et al. Nodal marginal zone Bcell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood 2001;98:781-786. https://doi.org/10.1182/blood.V98.3.781
  54. Nathwani BN, Drachenberg MR, Hernandez AM, Levine AM, Sheibani K. Nodal monocytoid B-cell lymphoma (nodal marginalzone B-cell lymphoma). Semin Hematol 1999;36:128-138.
  55. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC). Br J Haematol 1996;93:731-736. https://doi.org/10.1046/j.1365-2141.1996.d01-1711.x
  56. Chacon JI, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002;100:1648-1654.
  57. Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003;4:95-103. https://doi.org/10.1016/S1470-2045(03)00981-1
  58. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 2005;23:6415-6420. https://doi.org/10.1200/JCO.2005.05.018
  59. Arcaini L, Orlandi E, Scotti M, et al. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma 2004;4:250-252. https://doi.org/10.3816/CLM.2004.n.005
  60. Paydas S, Yavuz S, Disel U, Sahin B, Ergin M. Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase. Leuk Lymphoma 2003;44:2165-2166. https://doi.org/10.1080/1042819031000123555
  61. Hermine O, Lefrere F, Bronowicki JP, Mariette, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94. https://doi.org/10.1056/NEJMoa013376
  62. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non- Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005;23:468-473.

Cited by

  1. Primary extranodal marginal zone B-cell lymphoma of MALT-type involving the fallopian tube vol.2, pp.1, 2010, https://doi.org/10.1016/j.gynor.2011.10.005
  2. Synchronous Primary Low-grade Mucosa-associated Lymphoid Tissue Lymphoma of Colon and Stomach vol.11, pp.3, 2013, https://doi.org/10.5217/ir.2013.11.3.204
  3. Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party vol.48, pp.3, 2010, https://doi.org/10.5045/br.2013.48.3.171
  4. A Case of Complete Remission of Mucosa-associated Lymphoid Tissue Lymphoma of the Urinary Bladder after Eradication ofHelicobacter Pylori vol.87, pp.2, 2010, https://doi.org/10.3904/kjm.2014.87.2.229
  5. Prognostic impact of β2-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma vol.56, pp.3, 2010, https://doi.org/10.3109/10428194.2014.917640
  6. Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study vol.102, pp.4, 2010, https://doi.org/10.1007/s12185-015-1845-6
  7. Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era vol.10, pp.None, 2010, https://doi.org/10.1038/s41598-020-68310-w